Oridonin inhibits SARS-CoV-2 replication by targeting viral proteinase and polymerase.

ABSTRACT: COVID-19 has become a global public health crisis since its outbreak in China in December 2019. Currently there are few clinically effective drugs to combat SARS-CoV-2 infection. The main protein (M^pro), papain-like protease (PL^pro) and RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2 are involved in the viral replication, and might be prospective targets for anti-coronavirus drug development. Here, we investigated the antiviral activity of oridonin, a natural small-molecule compound, against SARS-CoV-2 infection in vitro. The time-of-addition analysis showed that oridonin efficiently inhibited SARS-CoV-2 infection by interfering with the genome replication at the post-entry stage. Mechanistically, the inhibition of viral replication by oridonin depends on the oxidat

SUBMITTER: Zhang Z 

PROVIDER: S-EPMC10148713 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature